Adma Biologics (ADMA) Total Debt (2012 - 2025)

Adma Biologics has reported Total Debt for 13 years, with the latest figure at $72.1 million in Q4 2025.

• For the quarter ending Q4 2025, Total Debt changed 0.27% year-over-year to $72.1 million; the trailing twelve-month figure through Dec 2025 stood at $72.1 million (changed 0.27% YoY), and the FY2025 full-year result was $72.1 million, changed 0.27% from the prior year.
• Total Debt for Q4 2025 stood at $72.1 million, roughly flat from $72.4 million in the prior quarter.
• The five-year high for Total Debt was $144.3 million in Q1 2023, with the low at $72.1 million in Q4 2025.
• Historically, Total Debt has averaged $111.1 million across 5 years, with a median of $116.0 million in 2023.
• Annual changes were most pronounced in 2021 — Total Debt soared 526.22% — and 2024, when it slumped 44.61%.
• Adma Biologics' Total Debt stood at $94.9 million in 2021, then jumped by 50.56% to $142.8 million in 2022, then declined by 8.57% to $130.6 million in 2023, then tumbled by 44.61% to $72.3 million in 2024, then slipped by 0.27% to $72.1 million in 2025.
• The last three Total Debt figures came in at $72.1 million (Q4 2025), $72.4 million (Q3 2025), and $73.4 million (Q2 2025), per Business Quant data.